Azurity, Takeda & Arbor v. Hetero Labs: Azilsartan Medoxomil Patent Dismissed Without Prejudice
Three pharmaceutical plaintiffs — Azurity Pharmaceuticals, Takeda Pharmaceutical, and Arbor Pharmaceuticals — filed a patent infringement action against Hetero Labs in Delaware over US9066936B2, a patent covering azilsartan medoxomil oral tablets. The case closed by mutual stipulation without prejudice after 238 days, with each side bearing its own costs.
ANDA patent battle over antihypertensive tablets ends in no-merits exit
On 28 March 2024, Azurity Pharmaceuticals, Takeda Pharmaceutical Company Limited, and Arbor Pharmaceuticals (collectively, Plaintiffs) filed suit in the District of Delaware against Hetero Labs, Ltd., Hetero Labs Limited, and Hetero USA, Inc., asserting infringement of US9066936B2 in connection with Hetero’s proposed generic azilsartan medoxomil oral tablets at 40 mg and 80 mg strengths. The case was assigned to Judge Maryellen Noreika, a court regularly handling Hatch-Waxman ANDA litigation.
The case closed on 21 November 2024 — 238 days after filing — when the parties filed a joint stipulation of dismissal under Federal Rule of Civil Procedure 41(a)(1)(A)(ii). All claims, counterclaims, and defenses were dismissed in their entirety without prejudice, and both sides agreed to bear their own attorney fees and costs. No merits determination was reached, and no damages were awarded.
A without-prejudice dismissal at this stage of an ANDA case typically suggests the parties reached a commercial resolution — most commonly a confidential settlement or license — without requiring judicial intervention, though the public record is silent on any underlying terms. The relatively swift resolution within 238 days, before claim construction or substantive motions, is consistent with early-stage settlement activity common in Hatch-Waxman disputes involving branded antihypertensive formulations.
Filing to Dismissed without Prejudice in 238 days
238 days from filing to dismissal — typical for early ANDA stipulated dismissals in Delaware
Dismissed without prejudice: what the stipulation means for both parties
Rule 41(a)(1)(A)(ii) stipulated dismissal — no merits ruling issued
A dismissal under Rule 41(a)(1)(A)(ii) requires agreement of all parties who have appeared and is self-executing upon filing. Because the dismissal is without prejudice, no final judgment on the merits was entered, and the claims are not extinguished. Plaintiffs retain the legal right to refile the same claims against Hetero, subject to applicable statutes of limitations and any private agreement between the parties.
No merits adjudicationWithout prejudice: the door remains open — but the terms are private
A without-prejudice dismissal preserves the plaintiff’s ability to refile, distinguishing it from a with-prejudice dismissal, which operates as a final judgment on the merits. The public docket does not disclose whether the parties reached a private settlement, licensing agreement, or simply agreed to pause litigation. Practitioners should note that any confidential terms — including potential authorized generic supply or launch date agreements — are not visible from the court record.
Refiling rights preservedPatent survives unchallenged — enforceability of US9066936B2 unchanged
Because no invalidity or non-infringement ruling was issued, US9066936B2 remains in force and fully enforceable. Azurity, Takeda, and Arbor retain the ability to assert the patent against Hetero or any other ANDA filer for azilsartan medoxomil tablets. The dismissal without prejudice is typically consistent with a negotiated resolution that protects the branded franchise while avoiding costly trial risk.
Patent enforceability intactHetero avoids invalidity finding — generic entry timeline remains uncertain
Hetero Labs secured a dismissal without any admission of infringement or invalidity determination. However, without a court ruling of non-infringement, Hetero’s pathway to commercial generic launch of azilsartan medoxomil tablets remains subject to any private agreement reached with Plaintiffs. Other generic filers in the azilsartan medoxomil space receive no collateral benefit from this dismissal, as no patent validity ruling was entered.
No invalidity ruling securedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Azurity Pharmaceuticals, Inc. | Company | Pharmaceutical IP holders — branded azilsartan medoxomil franchise, holder of US9066936B2Search in Eureka ↗ |
| Co-Plaintiff | Takeda Pharmaceutical Company Limited | Company | Search in Eureka ↗ |
| Co-Plaintiff | Arbor Pharmaceuticals, LLC | Company | Search in Eureka ↗ |
| Defendant | Hetero Labs, Ltd. | Company | Generic pharmaceutical manufacturer Hetero Labs seeking ANDA approval for azilsartan medoxomil tabletsSearch in Eureka ↗ |
| Co-Defendant | Hetero USA, Inc. | Company | Search in Eureka ↗ |
| Co-Defendant | Hetero Labs Limited | Individual | Search in Eureka ↗ |
| Plaintiff counsel | Alexandra M. Joyce | Attorney | Counsel for Azurity Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Bruce M. Wexler | Attorney | Counsel for Azurity Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Chad J. Peterman | Attorney | Counsel for Azurity Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Christopher P. Hill | Attorney | Counsel for Azurity Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Daniel M. Silver | Attorney | Counsel for Azurity Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Maliheh Zare | Attorney | Counsel for Azurity Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Michael F. Werno | Attorney | Counsel for Azurity Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Sarah E. Spencer | Attorney | Counsel for Azurity Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | McCarter & English LLP | Law Firm | Representing Azurity Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Stamatios Stamoulis | Attorney | Counsel for Hetero Labs, Ltd.Search in Eureka ↗ |
| Defendant law firm | Stamoulis & Weinblatt LLC | Law Firm | Representing Hetero Labs, Ltd.Search in Eureka ↗ |
| Presiding judge | Judge Maryellen Noreika | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulation expressly dismisses all claims, counterclaims, and defenses in their entirety without prejudice under Rule 41(a)(1)(A)(ii), and provides that each side bears its own attorney fees and costs. The breadth of the dismissal — covering all counterclaims and defenses, not just plaintiff claims — suggests a clean exit by mutual consent rather than a partial resolution. The absence of a fee-shifting award and the without-prejudice designation are consistent with a negotiated commercial arrangement, though no such terms appear on the public docket.
US9066936B2 — azilsartan medoxomil oral tablet formulation patent
US9066936B2 (application number US12/450403) covers formulations of azilsartan medoxomil, an angiotensin II receptor blocker (ARB) used in the treatment of hypertension. The patent’s claims are directed to oral tablet formulations at the clinically relevant 40 mg and 80 mg doses. Azilsartan medoxomil is the active ingredient in the branded product Edarbi, originally developed by Takeda and licensed to the branded pharmaceutical ecosystem including Azurity and Arbor Pharmaceuticals.
The commercial significance of US9066936B2 lies in its role as a formulation barrier against generic entry for a widely prescribed antihypertensive. With multiple ANDA filers typically entering the azilsartan medoxomil space, this patent has been and may continue to be asserted in Hatch-Waxman proceedings. The patent’s survival without any invalidity finding in this action strengthens its deterrent value against future generic challengers, particularly those without a negotiated entry agreement.
Should your ANDA reference azilsartan medoxomil 40 mg or 80 mg tablets? Run an FTO against US9066936B2.
Any generic pharmaceutical company that has filed or is considering filing an ANDA referencing azilsartan medoxomil oral tablets at 40 mg or 80 mg should treat US9066936B2 as a live enforcement risk. The patent emerged from this litigation with no validity challenge adjudicated. R&D teams developing formulation strategies for azilsartan medoxomil generics — including particle size, excipient selection, and tablet architecture — should assess whether their proposed formulation falls within the patent’s claim scope before committing to regulatory filing.
PatSnap Eureka’s FTO Search Agent can rapidly map the claim landscape of US9066936B2, identify prior art relevant to any invalidity arguments, and surface co-pending or related family members that may extend coverage. Eureka’s patent family analysis also flags any continuation or divisional applications that could present additional enforcement vectors beyond the granted patent, giving your IP and regulatory teams a complete risk picture before ANDA submission.
Run a freedom-to-operate analysis on US9066936B2 to assess your product’s exposure
Run FTO in Eureka →Similar Hatch-Waxman patent cases: azilsartan and ARB formulation disputes in Delaware
Cases involving antihypertensive formulation patents and ANDA challenges filed in Delaware District Court, with comparable dismissal or settlement outcomes.
What this case signals for the antihypertensive generics IP landscape
Early without-prejudice exits in ANDA cases often mask commercial deals. Here is what IP professionals should track.
Without-prejudice ANDA dismissals typically signal a negotiated entry date
In Hatch-Waxman litigation, stipulated dismissals without prejudice at the pre-claim-construction stage are strongly associated with confidential settlement agreements, often including a negotiated authorized generic arrangement or a defined launch date. IP teams monitoring the azilsartan medoxomil generic market should watch for Hetero’s commercial activity as a signal of any underlying deal terms.
US9066936B2 remains a live enforcement asset against all ANDA filers
Because the patent was not invalidated or adjudicated, Azurity, Takeda, and Arbor retain full enforcement rights. Any other generic manufacturer who has filed or is planning an ANDA referencing azilsartan medoxomil 40 mg or 80 mg tablets should conduct a freedom-to-operate analysis against US9066936B2 before committing to a launch date.
Azurity v Hetero — key questions answered
The without-prejudice dismissal means no merits ruling was entered on infringement or validity of US9066936B2. All claims and counterclaims were dropped by mutual stipulation under Rule 41(a)(1)(A)(ii). Plaintiffs retain the right to refile claims against Hetero, and the patent remains enforceable. No damages were awarded and each side bears its own costs.
The asserted patent is US9066936B2 (application number US12/450403), covering azilsartan medoxomil oral tablet formulations at 40 mg and 80 mg. The patent relates to antihypertensive ARB therapy and is associated with the branded product Edarbi. It was asserted in a Hatch-Waxman context against Hetero’s proposed generic version.
No. The case was dismissed without prejudice by joint stipulation before any substantive merits ruling. No claim construction, invalidity finding, or non-infringement determination was issued. US9066936B2 remains valid and enforceable as granted, and Hetero did not secure any judicial finding in its favour regarding the patent’s validity or scope.
The parties’ agreement to bear their own attorney fees and costs means no fee-shifting occurred under 35 U.S.C. § 285 or Rule 54. This is standard in consensual dismissals and suggests neither side sought to characterise the case as exceptional. It also avoids any satellite litigation over costs, consistent with a negotiated resolution rather than a litigated outcome.
The three plaintiffs are Azurity Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, and Arbor Pharmaceuticals, LLC. Together they hold or license rights in US9066936B2 covering azilsartan medoxomil tablet formulations. This multi-plaintiff structure is common in Hatch-Waxman cases where a branded drug has been developed by one party and commercialised through licensing arrangements with others.
PatSnap Eureka searches patents and litigation data to answer instantly.